Thank you for sharing!

Your article was successfully shared with the contacts you provided.

On March 22 the Federal Circuit issued its long anticipated en banc decision in Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co. More than 20 amicus briefs filed demonstrated the case’s importance to the patent community (see “Brief on Briefs”). So, what was so important, what was decided, what does it mean, and where are we going?

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2017 ALM Media Properties, LLC. All Rights Reserved.